Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes.…
18 analysts rate RYTM Buy on consensus.
Consensus price target: $143.94 (+61.24% upside from $89.27)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Meeker David P director, President and CEO | Sep 14, 2026 | Sale | 6,439 | $655.15K |
| Meeker David P director, President and CEO | Sep 14, 2026 | Sale | 30,746 | $3.15M |
| Meeker David P director, President and CEO | Sep 14, 2026 | Sale | 2,300 | $241.94K |
| Meeker David P director, President and CEO | Sep 14, 2026 | Sale | 8,698 | $899.63K |
| Meeker David P director, President and CEO | Sep 14, 2026 | Sale | 1,817 | $189.96K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $189.76M | +45.83% | $-196.54M |
| 2024 | $130.13M | +68.06% | $-260.6M |
| 2023 | $77.43M | +227.56% | $-184.68M |
Stock data for RYTM: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics